Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

BTIG upgraded Outlook Therapeutics stock to 'Buy' from 'Neutral'.

Outlook Therapeutics received regulatory approval for its wet AMD therapy.

The therapy could become a preferred anti-VEGF treatment option.

The US retina market is valued at $8.5 billion.

The stock upgrade is based on the therapy's market potential.